The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Retinoblastoma mutation to predict poor outcomes in non-small cell lung cancer (NSCLC).
 
Priyanka Bhateja
No Relationships to Disclose
 
Gary Wildey
No Relationships to Disclose
 
Pingfu Fu
No Relationships to Disclose
 
Mary Beth Lipka
No Relationships to Disclose
 
Fatemeh Ardeshir-Larijani
No Relationships to Disclose
 
Neelesh Sharma
Employment - Novartis
Stock and Other Ownership Interests - Arena Pharma; AVEO; Aviragen therapeutics; Edge Therapeutics, Inc.; GalMed Pharmacueticals; Idera; Immune Pharmaceuticals; ImmunoCellular Therapeutics; Intercept Pharmaceuticals; Merrimack; Opexa; Opexa; Opexa; Opexa; Peregrine Pharmaceuticals; Peregrine Pharmaceuticals; Peregrine Pharmaceuticals; Peregrine Pharmaceuticals; Rockwell Medical; Rockwell Medical
Consulting or Advisory Role - Bionest Partner; C1 consulting; LEK
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Incuron (Inst); Incuron (Inst); Incuron (Inst); Incuron (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Genentech/Roche; Genentech/Roche; Janssen Oncology; Janssen Oncology; Janssen Oncology; Merck; Merck; Merck; Novartis; Novartis; Novartis; Sanofi; Sanofi; Sanofi
 
Afshin Dowlati
Consulting or Advisory Role - ARIAD
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)